Skip to content Skip to footer
Subscribe Now
NEWS

Jazz Pharmaceuticals Enters a ~$1.03B Licensing Deal with Saniona for SAN2355

Shots:Jazz Pharmaceuticals has entered into a global license agreement with Saniona to develop SAN2355 for epilepsy & other potential indicationsAs per the deal, Jazz will lead & fund development, regulatory filings, & global commercialization in exchange for $42.5M upfront, ~$192.5M in development & regulatory milestones (incl. $7.5M at P-I initiation), ~$800M in commercial milestones, &…
August 21, 2025

Read more

NEWS

Avata Biosciences Enters a Co-Development and Licensing Deal with Oceanus Bio for AVAT-021 and AVAT-022 to Treat Epilepsy and Schizophrenia

Shots:Avata has entered into a co-development & licensing deal with Oceanus Bio for exclusive rights to AVAT-021 & AVAT-022 in Japan & Asia, excl. China & IndiaAs per the deal, Avata will receive $95M in co-development contributions, regulatory & sales milestones, plus double-digit royalties on sales, while Oceanus will lead regulatory activities &…
June 18, 2025

Read more

Disease of the Month – Epilepsy
INSIGHTS+

Disease of the Month – Epilepsy

Shots: Epilepsy is a chronic, non-communicable brain condition that affects neurons and causes recurring seizuresOur Disease of the Month report covers epidemiology, market size, current management strategies, emerging therapeutic options, and the role of patient advocacy groups. Additionally, we highlight the key industry players advancing treatments for epilepsyFor a detailed analysis and tailored…
January 21, 2025

Read more

Viewpoints_Jason Lerner
VIEWPOINTS

Transcending Epilepsy Care: Jason Lerner from Biohaven in an Enlightening Dialogue Exchange with PharmaShots

Shots: Epilepsy affects around 1.5 million people in the US and 50 million globally. With approximately 40% of epilepsy patients being drug-resistant, there is an urgent need for innovative therapies Today, at PharmaShots we have Dr. Jason Lerner from Biohaven shedding light on BHV-7000, an investigational anti-seizure treatment and selective activator of potassium channels in…
November 6, 2024

Read more

35th World Congress for Neurorehabilitation New Advances in Neurorehabilitation
EVENTS

35th World Congress for Neurorehabilitation: New Advances in Neurorehabilitation

Conference Series is delighted to welcome you to attend the “35th World Congress for Neurorehabilitation” to be held in Amsterdam, Netherlands, from August 07-08, 2023. The exhilarating scientific program will focus on Clinical Neurology, Cognitive Neuroscience Neurorehabilitation, Neurosurgery, Psychiatry. The two days program will be filled with insightful presentations, engaging discussions, and networking opportunities. This…
July 7, 2023

Read more

Disease of the Month: Epilepsy
INSIGHTS+

Disease of the Month: Epilepsy

INTRODUCTIONAlso known as seizure disorder, epilepsy is a non-communicable chronic disorder of the brain and is the fourth most common neurological disease globally. It is a central nervous system (CNS) disorder characterized by recurrent episodes of seizures that are short changes in normal brain activity which led to brief incidences of involuntary movements either…
November 16, 2022

Read more

Michael G. Chez and Greg Grunberg Share Insights from “The Care Giver” Series Based on Epilepsy
VIEWPOINTS

Michael G. Chez and Greg Grunberg Share Insights from “The Care Giver” Series Based on Epilepsy

Shots:Dr.Chez talked about the challenges faced in epilepsy diagnosis and its various treatment optionsGreg spoke about the new online series sponsored by Jazz Pharmaceuticals and how it benefits people with EpilepsyThe interview summarizes the vital role of caregivers in the lives of those living with epilepsySmriti: Can we talk about Epilepsy in…
August 22, 2022

Read more